The deal consideration is $53.00 per share in cash for an approximate equity value of $6.7 billion.The Financial Times was the first to report the deal.Pipeline Pressure Mounts Ahead Of Keytruda ExpiryThe deal reflects Merck's broader strategy to replenish its pipeline ahead of Keytruda's expected patent expiry as early as 2028.Keytruda, a cancer immunotherapy, generates about $30 billion annually, making it central to the company's growth trajectory.Merck has been among the most aggressive acquirers in bio ...